查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1476435

到 2030 年多形性胶质母细胞瘤治疗市场预测：按类型、药物类别、应用、最终用户和地区分類的全球分析

Glioblastoma Multiforme Treatment Market Forecasts to 2030 - Global Analysis By Type, Drug Class, Application, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球多形性胶质母细胞瘤治疗市场规模将达到 27.5 亿美元，预计在预测期内将以 11.7% 的复合年增长率增长，到 2030 年达到 59.6 亿美元。

化疗、放射线治疗和手术经常用于治疗多形性胶质母细胞瘤 (GBM)。手术的目标是在不损害重要大脑区域的情况下尽可能切除肿瘤。由于 GBM 细胞具有侵袭性，因此完全清除通常很困难。手术后，进行放射线治疗以瞄准任何剩余的癌细胞并缩小肿瘤。此外，治疗的下一步是化疗，其中Temozolomide通常用于进一步靶向和杀死癌细胞。

根据美国癌症协会的数据，癌症是美国第二大死因，仅次于心臟病。 2021 年，预计将诊断出约 1,898,160 例新癌症病例，608,570 名美国人将死于癌症。

脑肿瘤发生率增加

GBM 是全世界最常见的脑肿瘤之一。人口老化、环境暴露、遗传倾向和生活方式选择是这一趋势的促成因素。随着世界人口的持续成长和老化，GBM的发生率预计也会增加。此外，据报道，医学影像方法的进步促进了脑肿瘤的早期检测，也导致了盛行率的上升。

现有治疗方法的效果有限

儘管治疗方法有所改善，但现有治疗方法GBM 的效果仍有限。化疗、放射线治疗和手术切除术只能减缓疾病进展或缩小肿瘤大小，且只能提供短期缓解。然而，GBM细胞经常浸润大脑周围组织，使得手术切除变得困难并增加肿瘤復发的可能性。此外，血脑障壁会阻止标靶药物和化疗到达大脑，从而限制全身性治疗的有效性。

精准医疗领域发展

根据患者特定属性优化治疗计划被称为精准医学，为改善 GBM 的治疗结果提供了光明的前景。基因组序列测定技术和分子分析的最新发展使个人化治疗方法成为可能，这证明了 GBM 肿瘤的异质性。透过识别驱动肿瘤生长的精确基因变化和分子特征，临床医生可以选择不太可能产生脱靶效应的标靶治疗。此外，整合转录组学、蛋白质组学、代谢体学和基因组学等多组体学资料将有助于全面了解肿瘤生物学和治疗脆弱性。

肿瘤復发和抗治疗性

GBM治疗的一个主要障碍是抗治疗性，这可能导致肿瘤復发和疾病进展。化疗、放射线治疗和标靶药物是 GBM 细胞表现出内在和获得性抗药性的常见治疗方法。基因改变、替代信号途径的启动、细胞凋亡的逃避以及能够自我更新的癌症干细胞的存在都是抗药性机制的例子。此外，GBM肿瘤的高度侵袭性使得完全手术切除变得困难，留下残余疾病和再生的可能性。

COVID-19 的影响

GBM 治疗市场受到了 COVID-19 大流行的各种影响。疫情对世界各地医疗保健系统的最初影响导致 GBM 患者的诊断、治疗开始和临床试验入组的延迟，但长期影响却各不相同。一方面，疫情凸显了远端医疗解决方案和坚实的医疗基础设施的重要性，加速了虚拟照护服务模式和远端患者监护的采用。然而，财务限制、供应链中断和资源重新分配可能会给患者和医疗保健提供者带来挑战，并阻碍获得及时有效的 GBM 治疗。

手术领域预计将成为预测期内最大的区域

在多形性胶质母细胞瘤（GBM）的治疗方面，外科领域通常占最大的市场占有率。手术的目标是在保留神经功能的同时切除尽可能多的肿瘤，这是治疗 GBM 的重要组成部分。儘管 GBM 具有侵袭性，但手术切除是切除肿瘤和缓解症状的主要治疗选择。术中影像和萤光引导手术等现代方法正在帮助神经外科医生实现最安全的切除。然而，由于 GBM 细胞的侵袭性和脑损伤的可能性，完全手术切除通常很困难。

Temozolomide细分市场预计在预测期内具有最高的复合年增长率

在多形性胶质母细胞瘤（GBM）治疗市场中，Temozolomide细分市场的年复合成长率（CAGR）最高。Temozolomide是一种口服烷化剂，通常用作放射线治疗或手术切除后标准治疗计划的一部分。这种药物被广泛使用，因为它可以穿过血脑障壁，造成 DNA 损伤，并对快速分裂的癌细胞具有细胞毒性。此外，Temozolomide也用作辅助性治疗（也称为同步放射线治疗）中放射线治疗后的维持治疗。

占比最高的地区

在多形性胶质母细胞瘤（GBM）治疗市场中，北美通常占最大份额。这项优势由多种因素促成，包括 GBM 病例的高发病率、先进的医疗技术、长期的医疗基础设施以及对研发的大量投资。此外，北美主要医疗机构、学术研究中心和市场相关人员的集中促进了创新，并使 GBM 患者更容易采用尖端治疗方法。该地区在 GBM 治疗方面的行业领先地位部分归功于其强大的法律规范、有利的报销政策和支持性法规环境。

复合年增长率最高的地区：

对于多形性胶质母细胞瘤（GBM）治疗市场，亚太地区预计将以最高的复合年增长率成长。中国、印度、日本和韩国等国家 GBM 盛行率上升、医疗保健成本上升、使用最先进医疗设施的机会增加以及研发支出增加等因素正在推动这一增长。此外，该地区的市场成长也受到加强治疗设施、促进早期检测以及提高有关 GBM 的公众和专业知识等措施的影响。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球多形性胶质母细胞瘤治疗市场：依类型

  • 外科手术
  • 放射治疗
  • 化疗
  • 免疫疗法
  • 标靶治疗
  • 肿瘤治疗场 (TTF) 治疗
  • 其他类型

第六章全球多形性胶质母细胞瘤治疗市场：依药物类别

  • Temozolomide
  • Lomustine
  • Bevacizumab
  • Carmustine汀晶圆
  • 其他药物类别

第七章全球多形性胶质母细胞瘤治疗市场：依应用分类

  • 新诊断的神经胶母细胞瘤
  • 復发性神经胶母细胞瘤
  • 安宁疗护
  • 临床试验
  • 儿童神经胶母细胞瘤母细胞瘤
  • 其他用途

第八章全球多形性胶质母细胞瘤治疗市场：依最终用户分类

  • 医院
  • 门诊手术中心
  • 诊所
  • 其他最终用户

第九章全球多形性胶质母细胞瘤治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • F. Hoffmann-La Roche Ltd.
  • Agenus Inc.
  • Merck & Co., Inc.
  • Tocagen Inc.
  • AbbVie Inc.
  • Merrimack Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Orbus Therapeutics Inc.
  • Novartis AG
  • Activartis GmbH
  • DelMar Pharmaceuticals, Inc.
  • BTG International Ltd
  • GT Medical Technologies, Inc.
  • Celldex Therapeutics Inc.
Product Code: SMRC25981

According to Stratistics MRC, the Global Glioblastoma Multiforme Treatment Market is accounted for $2.75 billion in 2023 and is expected to reach $5.96 billion by 2030 growing at a CAGR of 11.7% during the forecast period. Chemotherapy, radiation therapy, and surgery are frequently used in the treatment of glioblastoma multiforme (GBM). The goal of surgery is to remove as much of the tumor as possible without endangering vital brain areas. Due to the infiltrative nature of GBM cells, complete removal is frequently difficult. Radiation therapy is used after surgery to target any cancer cells that may still be present and to reduce the tumor. Moreover, the next step in the treatment is chemotherapy, which frequently uses temozolomide to further target and kill cancer cells.

According to the American Cancer Society, Cancer is the second leading cause of death in the United States, exceeded only by heart disease. In 2021, about 1,898,160 new cancer cases are expected to be diagnosed and 608,570 Americans are projected to die from cancer.

Market Dynamics:

Driver:

Increased frequency of brain tumours

GBM is among the brain tumors that are becoming more commonplace globally. The aging of the population, exposure to the environment, genetic predispositions, and lifestyle choices are some of the factors that contribute to this trend. GBM incidence is predicted to increase in step with the world population's continued growth and aging. Furthermore, contributing to the reported rise in prevalence are developments in medical imaging and diagnostic methods that have made brain tumors easier to identify early.

Restraint:

Limited effectiveness of available therapies

The effectiveness of existing treatments for GBM is still restricted, even with improvements in treatment modalities. Chemotherapy, radiation therapy, and surgical resection can only delay the progression of the disease and reduce tumor size, offering only short-term relief. However, GBM cells frequently infiltrate the brain's surrounding tissue, making surgical removal difficult and increasing the likelihood of tumor recurrence. Additionally, the blood-brain barrier limits the effectiveness of targeted agents and chemotherapy by preventing them from reaching the brain through systemic therapies.

Opportunity:

Developments in the field of precision medicine

Optimizing treatment plans based on unique patient attributes is known as precision medicine, and it offers a bright future for enhancing GBM outcomes. Personalized treatment approaches have been made possible by the recent developments in genomic sequencing technologies and molecular profiling, which have demonstrated the heterogeneity of GBM tumors. Clinicians can select targeted therapies with a lower chance of off-target effects by identifying the precise genetic alterations and molecular signatures driving tumor growth. Furthermore, a thorough grasp of tumor biology and treatment vulnerabilities is made possible by the integration of multiomic data, such as transcriptomics, proteomics, metabolomics, and genomics.

Threat:

Tumour recurrence and therapeutic resistance

A major obstacle to the management of GBM is therapeutic resistance, which can result in tumor recurrence and the advancement of the disease. Chemotherapy, radiation therapy, and targeted agents are among the common treatment modalities to which GBM cells show both intrinsic and acquired resistance. Genetic alterations, the initiation of alternative signaling pathways, apoptosis avoidance, and the existence of cancer stem cells capable of self-renewal are examples of resistance mechanisms. Moreover, total surgical resection is difficult due to the highly infiltrative nature of GBM tumors, which leaves residual disease and the possibility of regrowth.

Covid-19 Impact:

The market for GBM treatments has been impacted by the COVID-19 pandemic in many ways. The pandemic's early effects on healthcare systems around the world caused delays in GBM patient diagnoses, starts of treatments, and enrolment in clinical trials; however, the long-term effects have been uneven. On the one hand, the pandemic accelerated the adoption of virtual care delivery models and remote patient monitoring by highlighting the significance of telemedicine solutions and robust healthcare infrastructure. However, financial limitations, disruptions in the supply chain, and the reallocation of resources have presented difficulties for both patients and healthcare providers, potentially preventing access to prompt and effective GBM treatment.

The Surgery segment is expected to be the largest during the forecast period

When it comes to treating glioblastoma multiforme (GBM), the surgery segment usually commands the largest market share. The goal of surgery is to remove as much of the tumor as possible while maintaining neurological function, which is a critical part of managing GBM. Surgical resection is still the main treatment option for debulking the tumor and reducing symptoms, even though GBM is infiltrative in nature. Modern methods like intraoperative imaging and fluorescence-guided surgery help neurosurgeons achieve the safest resection possible. However, because GBM cells are invasive and there is a chance of brain damage, complete surgical removal is frequently challenging.

The Temozolomide segment is expected to have the highest CAGR during the forecast period

In the market for Glioblastoma Multiforme (GBM) treatments, the temozolomide segment has the highest compound annual growth rate (CAGR). One of the mainstays of GBM chemotherapy is temozolomide, an oral alkylating agent that is often taken as part of the standard treatment plan after radiation therapy and surgical resection. Its widespread use is due to its capacity to cross the blood-brain barrier and cause DNA damage in order to cytotoxically affect rapidly dividing tumour cells. Moreover, temozolomide is used as maintenance therapy after radiation therapy in the adjuvant context (also referred to as concurrent chemoradiotherapy).

Region with largest share:

When it comes to the market for treatments for Glioblastoma Multiforme (GBM), North America usually has the largest share. Numerous elements contribute to this dominance, such as the high incidence of GBM cases, the sophisticated medical technology, the long-standing healthcare infrastructure, and the significant investments made in research and development. Furthermore, North America's concentration of major healthcare facilities, academic research centres, and market players encourages innovation and makes it easier for GBM patients to adopt cutting-edge treatment modalities. The region leads the industry in GBM treatment due in part to strong regulatory frameworks, favourable reimbursement policies, and a supportive regulatory environment.

Region with highest CAGR:

In the market for treatments for glioblastoma multiforme (GBM), the Asia-Pacific region is projected to grow at the highest CAGR. Factors like the rising prevalence of GBM, rising healthcare costs, increased access to cutting-edge medical facilities, and rising R&D spending in nations like China, India, Japan, and South Korea are driving this growth. Additionally, the growth of the market in the region is also influenced by initiatives to strengthen treatment facilities, advance early detection, and increase public and professional knowledge of GBM.

Key players in the market

Some of the key players in Glioblastoma Multiforme Treatment market include F. Hoffmann-La Roche Ltd., Agenus Inc., Merck & Co., Inc., Tocagen Inc., AbbVie Inc., Merrimack Pharmaceuticals Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Orbus Therapeutics Inc., Novartis AG, Activartis GmbH, DelMar Pharmaceuticals, Inc., BTG International Ltd, GT Medical Technologies, Inc. and Celldex Therapeutics Inc.

Key Developments:

In January 2024, Merck, a leading science and technology company, has announced a licensing agreement with US-based firm Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).

In December 2023, Agenus Inc., a leader in developing novel immunological agents to treat various cancers, today announced it has triggered the second development milestone payment under its global licensing agreement with Bristol Myers Squibb for BMS-986442, an Fc-enhanced bispecific TIGIT antibody. Agenus will receive a $25 million cash payment from Bristol Myers Squibb with the dosing of the first patient in the phase 2 dose expansion portion of the ongoing CA115-001 clinical trial of BMS-986442.

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

Types Covered:

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Tumor Treating Field (TTF) Therapy
  • Other Types

Drug Classes Covered:

  • Temozolomide
  • Lomustine
  • Bevacizumab
  • Carmustine Wafers
  • Other Drug Classes

Applications Covered:

  • Newly Diagnosed Glioblastoma
  • Recurrent Glioblastoma
  • Palliative Care
  • Clinical Trials
  • Pediatric Glioblastoma
  • Other Applications

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Glioblastoma Multiforme Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Surgery
  • 5.3 Radiation Therapy
  • 5.4 Chemotherapy
  • 5.5 Immunotherapy
  • 5.6 Targeted Therapy
  • 5.7 Tumor Treating Field (TTF) Therapy
  • 5.8 Other Types

6 Global Glioblastoma Multiforme Treatment Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Temozolomide
  • 6.3 Lomustine
  • 6.4 Bevacizumab
  • 6.5 Carmustine Wafers
  • 6.6 Other Drug Classes

7 Global Glioblastoma Multiforme Treatment Market, By Application

  • 7.1 Introduction
  • 7.2 Newly Diagnosed Glioblastoma
  • 7.3 Recurrent Glioblastoma
  • 7.4 Palliative Care
  • 7.5 Clinical Trials
  • 7.6 Pediatric Glioblastoma
  • 7.7 Other Applications

8 Global Glioblastoma Multiforme Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Ambulatory Surgical Centers
  • 8.4 Clinics
  • 8.5 Other End Users

9 Global Glioblastoma Multiforme Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 F. Hoffmann-La Roche Ltd.
  • 11.2 Agenus Inc.
  • 11.3 Merck & Co., Inc.
  • 11.4 Tocagen Inc.
  • 11.5 AbbVie Inc.
  • 11.6 Merrimack Pharmaceuticals Inc.
  • 11.7 Eli Lilly and Company
  • 11.8 Bristol-Myers Squibb Company
  • 11.9 Pfizer Inc.
  • 11.10 Orbus Therapeutics Inc.
  • 11.11 Novartis AG
  • 11.12 Activartis GmbH
  • 11.13 DelMar Pharmaceuticals, Inc.
  • 11.14 BTG International Ltd
  • 11.15 GT Medical Technologies, Inc.
  • 11.16 Celldex Therapeutics Inc.

List of Tables

  • Table 1 Global Glioblastoma Multiforme Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Glioblastoma Multiforme Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Glioblastoma Multiforme Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 4 Global Glioblastoma Multiforme Treatment Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 5 Global Glioblastoma Multiforme Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 6 Global Glioblastoma Multiforme Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 7 Global Glioblastoma Multiforme Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 8 Global Glioblastoma Multiforme Treatment Market Outlook, By Tumor Treating Field (TTF) Therapy (2021-2030) ($MN)
  • Table 9 Global Glioblastoma Multiforme Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 10 Global Glioblastoma Multiforme Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 11 Global Glioblastoma Multiforme Treatment Market Outlook, By Temozolomide (2021-2030) ($MN)
  • Table 12 Global Glioblastoma Multiforme Treatment Market Outlook, By Lomustine (2021-2030) ($MN)
  • Table 13 Global Glioblastoma Multiforme Treatment Market Outlook, By Bevacizumab (2021-2030) ($MN)
  • Table 14 Global Glioblastoma Multiforme Treatment Market Outlook, By Carmustine Wafers (2021-2030) ($MN)
  • Table 15 Global Glioblastoma Multiforme Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 16 Global Glioblastoma Multiforme Treatment Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Glioblastoma Multiforme Treatment Market Outlook, By Newly Diagnosed Glioblastoma (2021-2030) ($MN)
  • Table 18 Global Glioblastoma Multiforme Treatment Market Outlook, By Recurrent Glioblastoma (2021-2030) ($MN)
  • Table 19 Global Glioblastoma Multiforme Treatment Market Outlook, By Palliative Care (2021-2030) ($MN)
  • Table 20 Global Glioblastoma Multiforme Treatment Market Outlook, By Clinical Trials (2021-2030) ($MN)
  • Table 21 Global Glioblastoma Multiforme Treatment Market Outlook, By Pediatric Glioblastoma (2021-2030) ($MN)
  • Table 22 Global Glioblastoma Multiforme Treatment Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 23 Global Glioblastoma Multiforme Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 24 Global Glioblastoma Multiforme Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 25 Global Glioblastoma Multiforme Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 26 Global Glioblastoma Multiforme Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 27 Global Glioblastoma Multiforme Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.